Pathology Researcher obtains $438,000 to study Breast Cancer

2011 April 25

Dr. Chris Nicol from the Department of Pathology and Molecular Medicine at Queen's University has received $438,000 from the Canadian Breast Cancer Foundation (CBCF) to study a role for Peroxisome proliferator-activated receptor (PPAR)g in breast cancer.

His group will use established models to definitively show how PPARg stops breast tumour progression, and whether use of PPARg activators are a novel way to improve the quality of life for breast cancer patients. The long term goal will be to use these data to provide a basis for dietary supplementation with natural PPARg activators to prevent breast tumour-related deaths among the >22,000 Canadians diagnosed with this disease.